Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis

Journal of the American Geriatrics Society

Volumn 64, Issue 3, 2016, Pages 543-552

  Sinclair, Alan J ^a   Bode, Bruce ^b   Harris, Stewart ^c   Vijapurkar, Ujjwala ^d   Shaw, Wayne ^d   Desai, Mehul ^d   Meininger, Gary ^d  

^a ASTON UNIVERSITY   (United Kingdom)

^b Atlanta Diabetes Association   (United States)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

canagliflozin; older adults; Phase 3 study; SGLT2 inhibitor; type 2 diabetes mellitus

Indexed keywords

ANTIFUNGAL AGENT; CANAGLIFLOZIN; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

AGED; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC PATIENT; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; URINARY TRACT INFECTION; AGE; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG EFFECTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; MIDDLE AGED; MULTICENTER STUDY; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED;

EID: 84961833550     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.14028     Document Type: Article

References (34)

1. Kirkman MS, Briscoe VJ, Clark N, et al., Diabetes in older adults. Diabetes Care 2012; 35: 2650-2664.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al., Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140-149.
3. Booth GL, Kapral MK, Fung K, et al., Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: A population-based retrospective cohort study. Lancet 2006; 368: 29-36.
4. Meneilly GS, Knip A, Tessier D,. Diabetes in the elderly. Can J Diabetes 2013; 37: S184-S190.
5. Sinclair A, Morley J,. Frailty and diabetes. Lancet 2013; 382: 1386-1387.
6. American Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care 2015; 38: S1-S93.
7. Sinclair A, Morley JE, Rodriguez-Manas L, et al., Diabetes mellitus in older people: Position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J Am Med Dir Assoc 2012; 13: 497-502.
8. Morley JE, Sinclair A,. Individualising treatment for older people with diabetes. Lancet 2013; 382: 378-380.
9. Rosenstock J, Aggarwal N, Polidori D, et al., Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35: 1232-1238.
10. Bode B, Stenlöf K, Harris S, et al., Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55 to 80 years with type 2 diabetes. Diabetes Obes Metab 2015; 17: 294-303.
11. Stenlöf K, Cefalu WT, Kim K-A, et al., Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013; 15: 372-382.
12. Schernthaner G, Gross JL, Rosenstock J, et al., Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: A 52-week, randomized trial. Diabetes Care 2013; 36: 2508-2515.
13. Yale JF, Bakris G, Cariou B, et al., Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013; 15: 463-473.
14. Bode B, Stenlöf K, Sullivan D, et al., Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: A randomized trial. Hosp Pract 2013; 41: 72-84.
15. Cefalu WT, Leiter LA, Yoon K-H, et al., Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382: 941-950.
16. Lavalle-González FJ, Januszewicz A, Davidson J, et al., Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial. Diabetologia 2013; 56: 2582-2592.
17. Wilding JP, Charpentier G, Hollander P, et al., Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: A randomised trial. Int J Clin Pract 2013; 67: 1267-1282.
18. Stenlöf K, Cefalu WT, Kim KA, et al., Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: Findings from the 52-week CANTATA-M study. Curr Med Res Opin 2014; 30: 163-175.
19. Yale JF, Bakris G, Cariou B, et al., Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 2014; 16: 1016-1027.
20. Forst T, Guthrie R, Goldenberg R, et al., Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 2014; 16: 467-477.
21. Leiter LA, Yoon K-H, Arias P, et al., Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: A randomized, double-blind, Phase 3 study. Diabetes Care 2015; 38: 355-364.
22. Polidori D, Sha S, Ghosh A, et al., Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013; 98: E867-E871.
23. Devineni D, Morrow L, Hompesch M, et al., Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012; 14: 539-545.
24. Devineni D, Curtin CR, Polidori D, et al., Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol 2013; 53: 601-610.
25. Glassock RJ, Winearls C,. Ageing and the glomerular filtration rate: Truths and consequences. Trans Am Clin Climatol Assoc 2009; 120: 419-428.
26. Yamout HM, Perkovic V, Davies M, et al., Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol 2014; 40: 64-74.
27. Sinclair A, Bode B, Harris S, et al., Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: A pooled analysis of clinical studies. BMC Endocr Disord 2014; 14: 37.
28. Usiskin K, Kline I, Fung A, et al., Safety and tolerability of canagliflozin in patients with type 2 diabetes: Pooled analysis of phase 3 study results. Postgrad Med 2014; 126: 16-34.
29. INVOKANA (Canagliflozin) Tablets, for Oral Use [Package Insert]. Titusville, NJ: Janssen Pharmaceuticals, 2014.
30. Fulcher G, Matthews D, Perkovic V, et al., Efficacy and safety of canagliflozin used in conjunction with sulfonylurea in patients with type 2 diabetes mellitus: A randomized, controlled trial. Diabetes Ther 2015; 6: 289-302.
31. Neal B, Perkovic V, de Zeeuw D, et al., Efficacy and safety of canagliflozin, an inhibitor of sodium glucose co-transporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care 2015; 38: 403-411.
32. Neal B, Perkovic V, de Zeeuw D, et al., Rationale, design, and baseline characteristics of the canagliflozin cardiovascular assessment study (CANVAS)-A randomized placebo-controlled trial. Am Heart J 2013; 166: 217-223.
33. INVOKANA (Canagliflozin) 100-mg Film-Coated Tablets, for Oral Use [Summary of Product Characteristics]. Beerse, Belgium: Janssen-Cilag International NV, 2014.
34. Watts N, Bilezikian J, Usiskin K, et al., Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2016; 101: 157-166.